araag2/HINT huggingface dataset:
Clinical trial NCT02422381 (phase 1/phase 2, status: active, not recruiting)
Conditions: carcinoma, non-small-cell lung
ICD codes: D02.20, D02.21, D02.22
Drugs: mk-3475, gemcitabine
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Women or men with advanced, histologically proven NSCLC.

          -  Patients must have received at least one but no more than three prior systemic
             therapies for advanced disease.

          -  Any toxicity related to prior therapies that, in the opinion of the investigator,
             would potentially be worsened with anti-PD1 therapy or gemcitabine should be resolved
             to less than Grade 1.

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.

          -  Women of childbearing potential must have a negative pregnancy test

          -  Ability to give informed consent and comply with the protocol.

          -  Anticipated survival minimum 3 months.

          -  Prior therapy with investigational agents must have been completed at least 3 weeks
             prior to study enrollment.

          -  Patients must have normal organ and marrow function as seen on protocol-defined blood
             test results

          -  Archived tumor tissue (minimum of 8 slides for paraffin-embedded tumor tissue)
             available

          -  Measurable disease by RECIST 1.1 criteria.

          -  Treated brain metastases will be allowed, provided they are asymptomatic.

          -  Radiation for symptomatic lesions outside the Central nervous system (CNS) must have
             been completed at least 2 weeks prior to study enrollment.

        Exclusion Criteria:

          -  Prior therapy with any anti-PD-1, anti-PD-L1, or anti-CTLA4 antibody.

          -  Prior therapy with gemcitabine.

          -  Prior complications from radiation, such as history of radiation pneumonitis or
             pulmonary edema that, in the opinion of the investigator, may have risk of increasing
             toxicity with anti-PD1 therapy.

          -  Active autoimmune disease except vitiligo or stable hypothyroidism.

          -  Active and ongoing steroid use, except for non-systemically absorbed treatments (such
             as inhaled or topical steroid therapy for asthma, cardiopulmonary disease (COPD),
             allergic rhinitis).

          -  Active other malignancy, except for controlled basal cell skin carcinoma.

          -  HIV positive and/or Hepatitis B or C positive.

          -  Other medical or psychiatric conditions that in the opinion of the Principal
             Investigator would preclude safe participation in this protocol.
Clinical trial NCT02429804 (phase 1, status: terminated)
Conditions: hormone-resistant prostate cancer, metastatic malignant neoplasm in the bone, metastatic prostate carcinoma
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31
Drugs: fludeoxyglucose f-18, fluorine f 18 sodium fluoride
SMILES: [H]C(=O)[C@H]([18F])[C@@H](O)[C@H](O)[C@H](O)CO, [18F-]
Reason stopped: 
    accrual factor
  
Eligibility criteria:

        Inclusion Criteria:

          -  Provides written informed consent

          -  Diagnosed with mCRPC and painful bone metastases, referred for Xofigo (radium Ra 223
             dichloride)

          -  Able to remain still for duration of the imaging procedure (about one hour)

        Exclusion Criteria:

          -  Metallic implants
Clinical trial NCT02438215 (phase 1, status: completed)
Conditions: parkinson's disease
ICD codes: G20
Drugs: irx4204
SMILES: C\C(\C=C\[C@@H]1C[C@]1(C)C1=CC=C2C(=C1)C(C)(C)CCC2(C)C)=C/C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          1. Participant is 40-80 years of age, inclusive.

          2. Participant has a clinical diagnosis of PD based on the UK Brain Bank Criteria.

          3. Participant has Hoehn and Yahr stage < 3.

          4. Participant may be treated with PD symptomatic therapy on a stable dose for at least
             30 days prior to the Screening Visit. Dose levels of PD symptomatic therapies will
             remain stable through the patient's participation in the study, unless a change of
             dose level is indicated because of adverse events.

          5. Participant must be willing and able to provide informed consent.

          6. Females must be of either non-child bearing potential based on:

               -  post-menopausal for at least 2 years, or

               -  surgically sterilized If of child bearing potential, must be neither pregnant or
                  breastfeeding at Screening, and must be willing to avoid pregnancy by using
                  medically accepted contraception (use of an intrauterine device or use of a
                  double barrier method when engaging in sexual intercourse with a male partner)
                  for 4 weeks prior to and 4 weeks following the last dose of study medication.

        Exclusion Criteria:

          1. Has any form of parkinsonism other than idiopathic PD

          2. Are currently experiencing motor fluctuations (end of dose wearing off or dyskinesias)
             reflective of later stage PD

          3. Has evidence of dementia or significant cognitive dysfunction

          4. Has clinically significant abnormal laboratory value and/or clinically significant
             unstable medical or psychiatric illness.

          5. The subject has any disorder that may interfere with drug absorption, distribution,
             metabolism or excretion.

          6. The subject has evidence of clinically significant gastrointestinal, cardiovascular,
             hepatic, renal, hematological, neoplastic, endocrine, alternative neurological,
             immunodeficiency, pulmonary, or other disorder or disease.

          7. Pregnancy or breastfeeding
Clinical trial NCT02439190 (phase 1, status: completed)
Conditions: thrombosis
ICD codes: I81, K64.5, I51.3, I67.6, I74.11, I74.5, I74.8
Drugs: bms-986120, aspirin, clopidogrel
SMILES: CC(=O)OC1=CC=CC=C1C(O)=O, N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Healthy subjects as determined by no clinically significant deviation from normal in
             medical history, physical examination, ECGs and clinical laboratory determinations

          -  Body Mass Index (BMI) of 18 to 32 kg/m2 inclusive. BMI = weight (kg)/ [height (m)]2

          -  Females who are not of childbearing potential (i.e., who are post-menopausal or
             surgically sterile) and men ages 18 to 65, inclusive

          -  Azoospermic males and women who are not of child-bearing potential (i.e. are
             postmenopausal or surgically sterile; see section 3.3.3 for the definition of WOCBP)
             are exempt from contraceptive requirements. However, women must still undergo
             pregnancy testing as described in this section

        Exclusion Criteria:

          -  Evidence of organ dysfunction or any clinically significant deviation from normal in
             physical examination, vital signs, ECG or clinical laboratory determinations beyond
             what is consistent with the target population

          -  Any condition that could affect drug absorption

          -  Other protocol-defined exclusion criteria could apply
Clinical trial NCT02439216 (phase 1/phase 2, status: completed)
Conditions: muscular dystrophy, duchenne
ICD codes: G71.01
Drugs: edasalonexent, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Written informed consent from parent or legal guardian prior to participation and, for
             patients who are 7 years of age, written assent from patient

          -  Diagnosis of DMD based on a clinical phenotype with increased serum CK and the
             presence of a mutation in the dystrophin gene known to be associated with a DMD
             phenotype

          -  Ability to walk independently (assistive devices are permitted)

          -  Adequate immunization for influenza and varicella

        Exclusion Criteria:

          -  Use of corticosteroids within prior 6 months of treatment initiation or planning to
             initiate steroid therapy within the next 6 months

          -  Other prior or ongoing significant medical conditions

          -  Exposure to another investigational drug (such as eteplirsen or idebenone) within 28
             days prior to start of study treatment or ongoing participation in any other
             therapeutic clinical trial

               -  Note: There are separate criteria for patients who participated in Part A versus
                  newly enrolling patients. New patients must meet all of the Part A entry criteria
                  to participate in Part B.

        Patients who participated in Part A must meet the following criteria to participate in Part
        B:

          -  Completed Part A

          -  Continue to meet all of the Part A entry criteria, including an absence of safety
             concerns (however, patients may be ≥8 years of age)

        There are no entry criteria for Part C; all patients who complete Part B will automatically
        continue in Part C
Clinical trial NCT02457286 (phase 1, status: withdrawn)
Conditions: non-alcoholic fatty liver disease (nafld)
ICD codes: Z52.6, K71.8, K71.7, A06.4, C22.0, C22.3, K70.0
Drugs: metformin
SMILES: CSCC[C@H](N)C(O)=O
Reason stopped: 
    patients do not want to participate
  
Eligibility criteria:

        Inclusion Criteria:

          -  subjects between ages 18-80

          -  diagnosed with NAFLD by alanine aminotransferase

          -  (ALT) levels >1.5x the upper limit of normal with an otherwise nondiagnostic hepatic
             serology workup, ultrasound evidence, and/or histologically confirmed NAFLD within the
             past 1 year.

          -  The upper limit of normal for ALT will be defined as 35 U/L in males and 19 U/L in
             females

        Exclusion Criteria:

          -  A prior history of diabetes

          -  Failure to meet criteria for HbA1C screening

          -  Evidence of hepatic disorders

          -  Use of insulin or oral hypoglycemic agents

          -  eGFR <30

          -  Blood transfusion within past 3 months

          -  Steroid use in the past 6 months

          -  Excessive alcohol use (more than 20g per day in women and more than 30g per day in
             men)

          -  Acute or unstable congestive heart failure

          -  Age >80 years old

          -  Lactic acidosis

          -  Inability to consent due to cognitive impairment.

          -  Pregnancy
Clinical trial NCT02459886 (phase 1, status: completed)
Conditions: parkinson's disease, healthy
ICD codes: G20, Z76.3, Z76.2
Drugs: biib054, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Key Inclusion Criteria:

          1. All women of childbearing potential and all men must practice effective contraception
             during the study and for 6 months after their last dose of study treatment.

          2. Must have a body mass index from 19 to 32 kg/m2, inclusive.

          3. Must be in good health as determined by the Investigator, based on medical history,
             physical examination, and 12-lead ECG.

             For cohort 7 only:

          4. Diagnosis of idiopathic PD

        Key Exclusion Criteria:

          1. History of cardiovascular disease.

          2. Subject smokes more than 5 cigarettes or the equivalent in tobacco daily.

          3. Surgery within 3 months prior to Day -1 (other than minor cosmetic surgery and minor
             dental surgery, as determined by the Investigator).

          4. History or positive test result for hepatitis C, hepatitis B, or human
             immunodeficiency virus (HIV).

          5. Female subjects who are pregnant, currently breastfeeding, or attempting to conceive
             during the study.

        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Clinical trial NCT02459938 (phase 1, status: completed)
Conditions: hypoglycemia
ICD codes: E16.1, E16.2, P70.3, P70.4, E16.0, E10.641, E10.649
Drugs: glucagon (zp-glucagon), glucagon (glucagen)
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Women or men 18 to 60 years with type-1 diabetes on daily insulin treatment
             (basal-bolus injection regimen or insulin pump) for at least two years, on a total
             daily dose that has been stable for the last 3 months preceding enrollment (no more
             than 20% variation), and with a current level of glycated hemoglobin between 6.5% and
             10%

        Exclusion Criteria:

          -  Any history of hypoglycemic coma or hypoglycemic seizures.

          -  Any episode of severe hypoglycemia (requiring treatment) within one month prior to
             study start.

          -  Any history of pheochromocytoma or insulinoma
Clinical trial NCT02465983 (phase 1, status: terminated)
Conditions: pancreatic cancer
ICD codes: C25.3
Drugs: cyclophosphamide
SMILES: ClCCN(CCCl)P1(=O)NCCCO1
Reason stopped: 
    lack of efficacy and funding to continue investigation
  
Eligibility criteria:

        Inclusion Criteria:

          -  Signed informed consent

          -  Unresectable or metastatic pancreatic cancer

          -  Persistent cancer after at least one prior standard of care chemotherapy for advanced
             stage disease

          -  18 years of age and older

          -  ECOG performance status of 0 or 1

          -  Life expectancy greater than 3 months

          -  Satisfactory organ and bone marrow function

          -  Meets blood coagulation parameters

          -  Male and Female subjects of reproductive potential agree to use approved contraceptive
             methods

        Exclusion Criteria:

          -  Participation in a therapeutic investigational study within 4 weeks prior to the
             screening visit

          -  Anticipated need for systemic chemotherapy within 2 weeks before apheresis and
             infusion

          -  Active invasive cancer other than pancreatic cancer

          -  HIV, HCV, or HBV infections

          -  Active autoimmune disease requiring immunosuppressive therapy within 4 weeks prior to
             screening visit, with exception of thyroid replacement

          -  Ongoing or active infection

          -  Planned concurrent treatment with systemic high dose corticosteroids

          -  Patients requiring supplemental oxygen therapy

          -  Prior therapy with gene modified cells

          -  Previous experimental therapy with SS1 moiety, murine or chimeric antibodies

          -  History of allergy to murine proteins

          -  History of allergy or hypersensitivity to study product excipients (human serum
             albumin, DMSO, and Dextran 40)

          -  Clinically significant pericardial effusion, CHF, or cardiovascular condition that
             would preclude assessment of mesothelin induced pericarditis or that may worsen as a
             result of toxicities expected for this study

          -  Pregnant or breastfeeding women
Clinical trial NCT02468661 (phase 1, status: terminated)
Conditions: non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: inc280 single agent, erlotinib
SMILES: COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2
Reason stopped: 
    major challenge for enrollment of participants.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Locally advanced or metastatic NSCLC

          -  EGFR mutation (L858R and /or ex19del)

          -  cMET amplification by FISH (GCN ≥ 6),

          -  Acquired resistance to EGFR TKI (1st or 2nd generation)

          -  ECOG performance status (PS) ≤ 1.

        Exclusion Criteria:

          -  Prior treatment with 3rd generation TKI

          -  PhaseII : Prior treatment with any of the following agents:

               -  Crizotinib, or any other cMET inhibitor or HGF-targeting inhibitor.

               -  Concomitant EGFR TKI and platinum based chemotherapy as first line regimen.

               -  Platinum-based chemotherapy as first line treatment
Clinical trial NCT02472795 (phase 1/phase 2, status: completed)
Conditions: systemic lupus erythematosus
ICD codes: M32.9, M32.0, M32.11, M32.12, M32.13, M32.14, M32.8
Drugs: matching placebo, cenerimod
SMILES: CC1=CC(O)=CC(C)=C1Cl, CCC1=CC(=CC(C)=C1OC[C@@H](O)CO)C1=NOC(=N1)C1=CC(=NC(OC)=C1)C1CCCC1
Eligibility criteria:

        Inclusion Criteria:

          -  Male and female participants aged 18 to 65 years with established SLE. Participants
             must have active SLE, Systemic Lupus Erythematosus Disease Activity Index-2000
             (SLEDAI-2K) score of at least 2 points for musculoskeletal or mucocutaneous
             manifestations and history or presence at screening of positive anti-nuclear
             antibodies (ANA) or anti-double-stranded DNA (anti-dsDNA) antibodies.

          -  Enrolled participants must be treated with background SLE medications.

        Exclusion Criteria:

          -  Participants with significant medical conditions or therapies for such conditions
             (e.g., cardiovascular, pulmonary, immunological, hepatic, ophthalmological, infection
             and infection risks, history or presence of malignancy, history or presence of bone
             marrow or solid organ transplantation) or lactating or pregnant women.

          -  Participants with severe SLE disease or with clinically relevant medical or surgical
             conditions that, in the opinion of the investigator, would put the subject at risk by
             participating in the study.
Clinical trial NCT02473367 (phase 1, status: completed)
Conditions: hiv infection
ICD codes: Z21
Drugs: raltegravir 1200 mg, tums, leader antacid
SMILES: CN1C(=O)C(O)=C(N=C1C(C)(C)NC(=O)C1=NN=C(C)O1)C(=O)NCC1=CC=C(F)C=C1, [Ca++].[O-]C([O-])=O, [Ca++].[O-]C([O-])=O
Eligibility criteria:

        Inclusion Criteria:

          -  Is HIV positive

          -  Is on a stable raltegravir-containing (400 mg every 12hr) antiretroviral (ARV) regimen
             for at least 1 month prior to study entry, with no changes, including dose
             adjustments; and agrees to maintain their current ARV therapy throughout the study.

          -  Be male, or a non-pregnant and non-breast feeding female at least 18 years of age at
             the pre-trial (screening)

          -  Has a Body Mass Index (BMI) =< 32 kg/m^2

        Exclusion Criteria:

          -  Has a history of clinically significant endocrine, gastrointestinal, cardiovascular,
             hematological, hepatic, immunological, renal, respiratory, genitourinary or major
             neurological (including stroke and chronic seizures) abnormalities or diseases
             (excluding HIV)

          -  Has a history of gastric bypass surgery

          -  Has a history of cancer (malignancy)

          -  Has a history of chronic diarrhea within approximately 3 months prior to the pre-trial
             visit

          -  Has a history of significant multiple and/or severe allergies (e.g. food, drug, latex
             allergy), or has had an anaphylactic reaction or significant intolerability to
             prescription or non-prescription drugs or food

          -  Has had major surgery, donated or lost 1 unit of blood (approximately 500 mL) within 4
             weeks prior to the pre-trial visit

          -  Has participated in another investigational trial within 4 weeks prior to the
             pre-trial visit

          -  Is currently taking rifampin or atazanavir or is unable to refrain from the use of 1)
             any proton pump inhibitor from two weeks prior to the study through the completion of
             Period 4, and 2) any H2-blockers, over-the-counter antacids, calcium supplements or
             multivitamins from one week prior to the study through the completion of Period 4

          -  Consumes greater than 3 glasses of alcoholic beverages or distilled spirits per day

          -  Consumes greater than 6 servings of coffee, tea, cola, energy-drinks, or other
             caffeinated beverages per day

          -  Is currently a regular user (including "recreational use") of any illicit drugs or has
             a history of drug (including alcohol) abuse within approximately 6 months of screening
Clinical trial NCT02481180 (phase 1, status: terminated)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: t0001, t0001, t0001, t0001, enbrel
SMILES: O
Eligibility criteria:

        Inclusion Criteria:

          -  Age 18-45 years old;

          -  Diagnosed with active RA;

          -  DMARDs therapy must not be used for at least 28 days prior to baseline;

          -  If a patient has received NSAIDs，current NSAIDs therapy must have been at a stable
             dose for at least 28 days prior to baseline;

          -  Patient or patient's legal representative able to give written informed consent for
             participation in the trial.

        Exclusion Criteria:

          -  Acute or chronic infection, or history of active tuberculosis;

          -  History of diseases of central nervous system, cardiovascular system, kidney, liver (
             specified liver function index), digestive system, respiratory system , metabolism
             system;

          -  Patients who have a high risk of infection (with a current infectious disease, a
             chronic infectious disease, a history of serious infectious disease);

          -  Patients who use 5 Unit doses tuberculin skin test are positive( 48-72 hour scleroma
             reading≥5mm);

          -  Patients who currently have, or who have a history of, malignancy;

          -  Patients who lack of understanding ,communication or collaboration, and can't comply
             with the protocols;

          -  Female patients who are breastfeeding or pregnant, who are of childbearing potential.
Clinical trial NCT02485249 (phase 1/phase 2, status: terminated)
Conditions: macular edema
ICD codes: H59.033, H34.8130, H59.031, H59.032, H59.039, H34.8110, H34.8120
Drugs: dexamethasone phosphate ophthalmic
SMILES: [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Reason stopped: 
    slow enrollment
  
Eligibility criteria:

        Inclusion Criteria:

          -  1. Age 18 to 90 years 2. Have diagnosis of ME secondary to one of the following
             diagnosed conditions:

               1. Central or branch retinal vein occlusion (CRVO or BRVO) with a mean CST ≥ 300µm
                  on SD-OCT images taken at the baseline visit (Day 0)

               2. Diabetic macular edema (DME) with a mean CST ≥ 300µm on SD-OCT images taken at
                  the baseline visit (Day 0)

               3. Cystoid macular edema (CME) secondary to having undergone a previous PPV and
                  having a mean CST ≥ 300µm on SD-OCT images taken at the baseline visit (Day 0)
                  having a history of previous positive response to steroid treatment 3. Receive,
                  understand, and sign a copy of the ICF 4. Be able to return for all study visits
                  and willing to comply with all study related instructions

                  Exclusion Criteria: